CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITPRNewsWire • 03/19/24
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/13/24
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesGlobeNewsWire • 03/04/24
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewsWire • 03/01/24
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundGlobeNewsWire • 02/28/24
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/23
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 MillionGlobeNewsWire • 11/01/23
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19PRNewsWire • 09/27/23
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic CancerPRNewsWire • 09/26/23
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMAPRNewsWire • 09/18/23
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/11/23
Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast CancerPRNewsWire • 08/10/23
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive DeclineGlobeNewsWire • 06/16/23
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTONPRNewsWire • 06/15/23
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex PharmaceuticalsGlobeNewsWire • 05/24/23
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19PRNewsWire • 04/20/23